From the biology perspective, monoclonal antibody production is hard, expensive and time-consuming. I don't think you'll see a rapid scale-up of these, as manuf

From the biology perspective, monoclonal antibody production is hard, expensive and time-consuming. I don't think you'll see a rapid scale-up of these, as manufacturing at scale is so different to manufacturing in small batches. Recombinant monoclonal antibodies seem like an interesting approach, these would speed up production by shortening the critical chain.